Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Consensus on the Management of Primary Localized Chordoma.

JAMA oncology·2026
Same author

Accuracy of the rapid-response electroencephalography's Automated Seizure Burden Estimator: A follow-up validation study of version 8 (AccuRASE II).

Epilepsia·2026
Same author

Effects of Normocalcemic Hyperparathyroidism on Structural Bone Compromise: A Prospective Observational Cohort Study.

Journal of bone metabolism·2026
Same author

Prognosis of critically ill patients with cirrhosis and acute kidney injury initiated on dialysis.

BMC nephrology·2026
Same author

Small bone replacement leads to greater gait asymmetry, cartilage damage, and osteophyte formation than ligament injury in a porcine wrist model.

Osteoarthritis and cartilage open·2026
Same author

External Evaluation Reveals Reduced Performance of the PathFX Survival Model in 1018 Patients With Extremity Metastases.

Clinical orthopaedics and related research·2026

Related Experiment Video

Updated: Jul 1, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

ASPH Is a Metastatic Factor and Therapeutic Target in Chondrosarcoma.

Xiaojuan Sun1, Jesse Hart2, Ross Taliano2

  • 1Department of Orthopaedics, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.

Cancers
|March 28, 2025
PubMed
Summary

Aspartate β-hydroxylase (ASPH) is a promising biomarker and therapeutic target for chondrosarcoma. Inhibiting ASPH with a small molecule inhibitor reduced tumor growth and metastasis in preclinical models.

Keywords:
ASPH knockoutbone cancerchondrosarcomametastasisprecision medicinesarcomasmall molecule inhibitortargeted therapy

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Experiment Videos

Last Updated: Jul 1, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Chondrosarcoma (CS) is an aggressive bone cancer lacking effective systemic treatments.
  • Aspartate β-hydroxylase (ASPH), a transforming cell surface receptor, has an unexamined role in CS.
  • This study investigates ASPH's expression, biomarker utility, and therapeutic potential in CS.

Purpose of the Study:

  • To analyze ASPH expression in conventional chondrosarcoma.
  • To evaluate ASPH as a prognostic biomarker.
  • To determine if ASPH inhibition impacts CS progression in preclinical models.

Main Methods:

  • ASPH expression quantified via immunohistochemistry on a chondrosarcoma tissue microarray.
  • ASPH small molecule inhibitor (SMI) tested in CS cell lines (wild-type and ASPH knockout).
  • In vitro assays measured cell viability, invasion, and matrix metalloproteinase (MMP) secretion; in vivo studies used a mouse xenograft model.

Main Results:

  • Higher ASPH expression correlated with increased risk of death and metastasis.
  • ASPH SMI reduced CS cell proliferation, invasion, and MMP secretion in vitro; effects abolished by ASPH knockout.
  • In vivo, SMI treatment decreased tumor growth, MMP activity, and lung metastasis in xenografts.

Conclusions:

  • ASPH is validated as a biomarker for chondrosarcoma and its metastatic potential.
  • Systemic ASPH inhibition shows therapeutic promise for chondrosarcoma.
  • Targeting ASPH represents a potential novel treatment strategy for ASPH-expressing chondrosarcoma.